Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619207 | 0.95 | TRPV1 (0.37) | KDM1ATRPV1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6559908 | 0.87 | TRPV1 (0.39) | KDM1ATRPV1 | |
| SCHEMBL4348315 | 0.87 | RAF1 (0.41) | KDM1AHTR2AHTR2CHTR2BDRD2 | |
| Hydrochloric Acid SCHEMBL6558690 | 0.85 | TRPV1 (0.40) | KDM1ATRPV1HTR2AHTR2CHTR2B | |
| SCHEMBL3322340 | 0.84 | TRPV1 (0.43) | KDM1ATRPV1HTR2ADRD2 | |
| SCHEMBL618100 | 0.84 | TRPV1 (0.43) | KDM1ATRPV1HTR2ADRD2 | |
| SCHEMBL3323591 | 0.84 | TRPV1 (0.43) | KDM1ATRPV1HTR2ADRD2 | |
| Ammonia Solution, Strong SCHEMBL13685415 | 0.82 | TRPV1 (0.42) | KDM1ATRPV1HTR2ADRD2 | |
| SCHEMBL17761478 | 0.81 | KCNH2 (0.35) | TRPV1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4352829 | 0.79 | MAPT (0.44) | KDM1AHTR2CSLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598220-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-7622493-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
| EP-2012778-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007121299-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233953-A1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | OPRL1, AVPR1A, TRPV1 | KDM1A 1439/4885TRPV1 3/4885HTR2A 278/4885 |
| US-20070249614-A1 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof | OPRL1, AVPR1A, AVPR1B | KDM1A 1393/4885TRPV1 4/4885HTR2A 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.